[go: up one dir, main page]

MX2022015400A - Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette. - Google Patents

Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.

Info

Publication number
MX2022015400A
MX2022015400A MX2022015400A MX2022015400A MX2022015400A MX 2022015400 A MX2022015400 A MX 2022015400A MX 2022015400 A MX2022015400 A MX 2022015400A MX 2022015400 A MX2022015400 A MX 2022015400A MX 2022015400 A MX2022015400 A MX 2022015400A
Authority
MX
Mexico
Prior art keywords
inhibitor
tourette syndrome
phosphodiesterase
treatment
formula
Prior art date
Application number
MX2022015400A
Other languages
English (en)
Inventor
George Garibaldi
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of MX2022015400A publication Critical patent/MX2022015400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar el Síndrome de Tourette en un sujeto que lo necesite mediante la administración al sujeto de composiciones que comprenden un inhibidor de la PDE10. También se describen formas sólidas cristalinas del compuesto de Fórmula I y usos del mismo: (ver Fórmula).
MX2022015400A 2020-06-05 2021-06-04 Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette. MX2022015400A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035310P 2020-06-05 2020-06-05
US202163160302P 2021-03-12 2021-03-12
PCT/EP2021/065074 WO2021245280A1 (en) 2020-06-05 2021-06-04 Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome

Publications (1)

Publication Number Publication Date
MX2022015400A true MX2022015400A (es) 2023-03-16

Family

ID=76325557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015400A MX2022015400A (es) 2020-06-05 2021-06-04 Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette.

Country Status (13)

Country Link
US (1) US11883385B2 (es)
EP (1) EP4161526A1 (es)
JP (2) JP7748974B2 (es)
KR (2) KR20250171459A (es)
CN (1) CN116137811B (es)
AU (1) AU2021285225A1 (es)
BR (1) BR112022024751A2 (es)
CA (1) CA3180793A1 (es)
CL (2) CL2022003400A1 (es)
IL (1) IL298713A (es)
MX (1) MX2022015400A (es)
PH (1) PH12023550007A1 (es)
WO (1) WO2021245280A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022162193A1 (en) * 2021-01-28 2022-08-04 Noema Pharma Ag Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
JP2007523152A (ja) * 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8349824B2 (en) * 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
ME02419B (me) 2011-08-25 2016-09-20 Merck Sharp & Dohme Inhibitori pirimidina pde10
CA2879020C (en) * 2012-07-12 2021-02-09 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of tourette's syndrome
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
SI2991984T1 (sl) 2013-04-30 2017-05-31 F. Hoffmann-La Roche Ag Povezovanje pirazolovih amidov, katalizirano s paladijem

Also Published As

Publication number Publication date
JP7748974B2 (ja) 2025-10-03
CN116137811A (zh) 2023-05-19
US20240390339A1 (en) 2024-11-28
IL298713A (en) 2023-02-01
KR20250171459A (ko) 2025-12-08
EP4161526A1 (en) 2023-04-12
KR102892626B1 (ko) 2025-11-28
WO2021245280A1 (en) 2021-12-09
US11883385B2 (en) 2024-01-30
JP2025183391A (ja) 2025-12-16
CL2022003400A1 (es) 2023-07-28
AU2021285225A1 (en) 2023-01-19
PH12023550007A1 (en) 2024-03-11
BR112022024751A2 (pt) 2023-03-07
WO2021245280A9 (en) 2022-01-27
CN116137811B (zh) 2026-01-09
JP2023528896A (ja) 2023-07-06
KR20230040978A (ko) 2023-03-23
US20230149372A1 (en) 2023-05-18
CL2025002636A1 (es) 2025-11-28
CA3180793A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CO2023008167A2 (es) Inhibidores de prmt5
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
MX2021007833A (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer.
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
EA202192433A1 (ru) Соединения, полезные в терапии вич
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
ECSP109900A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
PH12023550160A1 (en) Combinations for the Treatment of Cancer
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2024004874A (es) Compuestos heterociclicos para uso en el tratamiento de cancer.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
UY39865A (es) Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer
CL2025002636A1 (es) Uso inhibidor de pde10 para tratamiento del síndrome de tourette (divisional de solicitud no. 202203400)
UY38972A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
MX2021015319A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.
MX2025002228A (es) Metodos para el tratamiento o la profilaxis de la endometriosis